FACT vs. AABB Cellular Therapy Accreditation: Which Does Your Program Need?
Last updated: April 2026
Both FACT and AABB accredit cellular therapy programs — but they serve different market requirements and are not interchangeable for CAR-T programs seeking commercial manufacturer access, payer network inclusion, or Medicare billing eligibility. Understanding the distinction before applying prevents programs from investing months of preparation in the wrong accreditation standard.
The Short Answer
If your program administers or plans to administer commercial CAR-T therapies (Kymriah, Yescarta, Breyanzi, Carvykti), pursues Blue Cross Blue Shield Blue Distinction Center for Transplants designation, or seeks Medicare reimbursement eligibility for FDA-approved CAR-T therapies — FACT accreditation is required. AABB accreditation does not satisfy these requirements.
If your program operates both cellular therapy services and traditional transfusion medicine or blood banking activities, AABB accreditation may also be appropriate — and IHS can manage dual-standard preparation in a single engagement.
Programs building new CAR-T capabilities from scratch should pursue FACT first, under the FACT-JACIE 9th Edition (effective February 2, 2026), with AABB as an optional parallel track if the program's scope warrants both.
FACT vs. AABB: Side-by-Side Comparison
| Factor | FACT Accreditation | AABB Accreditation (Cellular Therapy) |
|---|---|---|
| Administering Body | Foundation for the Accreditation of Cellular Therapy (FACT) — founded 1996 by ISCT and ASTCT | AABB (formerly American Association of Blood Banks) — founded 1947, broader blood banking and transfusion medicine scope |
| Current Standards Version | FACT-JACIE 9th Edition (effective February 2, 2026); FACT IEC Standards for CAR-T; 2022 Cord Blood Standards | AABB 12th Edition Standards for Cellular Therapy Services (effective July 1, 2025) |
| Inspection Cadence | 3-year accreditation cycle; on-site peer inspector survey; Annual Report required at 1-year post-accreditation; Renewal Report 14 months before 3-year expiration | 24-month inspection cycle |
| CAR-T Manufacturer Access | Required or strongly recommended by Novartis (Kymriah), Kite-Gilead (Yescarta), BMS (Breyanzi), and Janssen (Carvykti) for authorized treatment center status | Not a stated requirement for commercial CAR-T manufacturer access |
| Blue Distinction Center for Transplants | Required — BCBS Blue Distinction Center designation requires full FACT accreditation including IEC Standards compliance; gates reimbursement for $375,000–$450,000+ CAR-T infusions | Does not satisfy Blue Distinction Center designation requirements |
| Medicare CAR-T Coverage | FDA-approved CAR-T therapies covered under Medicare when administered at FACT-accredited programs | Medicare CAR-T coverage is tied to FACT accreditation, not AABB |
| Compliance Crosswalk Requirement | Required — central document mapping every FACT standard to internal SOPs and quality documents; must be submitted to FACT before inspection can be scheduled | Documentation approach differs; less emphasis on a single central Crosswalk document |
| Collection for Further Manufacturing | FACT 2024 specification requires facilities to specify collection intent; hospitals supplying apheresis products to pharma manufacturers must specify Collection for Further Manufacturing | AABB 12th Edition addresses ISBT 128 labeling and operational mechanics for cellular therapy |
| ISBT 128 Labeling | Required under 9th Edition for products intended for further manufacturing | AABB 12th Edition emphasizes ISBT 128 labeling conformity |
| Community Oncology Programs | FACT Community CAR T Working Group has developed fit-for-purpose IEC standards for community settings — not limited to academic transplant centers | No equivalent community-specific cellular therapy pathway |
| Cord Blood Banks | Separate 2022 FACT Standards for Cord Blood Banks — 500-unit minimum before inspection eligibility | AABB covers cord blood banking under broader cellular therapy standards |
| State Regulatory Recognition | California CCS Program mandates FACT for bone marrow transplants in patients under 21; New York state licensing for HPC operations uses NetCord-FACT standards | AABB recognized for blood banking operations in most states; cellular therapy state recognition varies |
| Consulting Engagement Cost | $150,000 to $350,000+ for comprehensive end-to-end new program development; lower for targeted gap analysis or mock inspection | Varies — typically lower than full FACT engagement due to shorter preparation timeline and different documentation requirements |
Decision Framework: FACT, AABB, or Both?
Pursue FACT If:
- Your program administers or plans to administer commercial CAR-T therapies — FACT is required for authorized treatment center status with all major manufacturers
- Your program seeks Blue Cross Blue Shield Blue Distinction Center for Transplants designation — required for BCBS reimbursement of CAR-T infusions
- Your program seeks Medicare billing eligibility for FDA-approved CAR-T therapies
- You operate a hematopoietic cell transplant (HCT) program and need to maintain or achieve FACT accreditation for allogeneic or autologous transplant activities
- You are a community oncology hospital building a new CAR-T program under FACT's Community IEC Standards
- Your apheresis center has been approached by a pharma manufacturer to supply leukapheresis starting materials — FACT's Collection for Further Manufacturing specification is required
- You operate in California (CCS Program) or New York (HPC licensing) where FACT accreditation or NetCord-FACT standards are state requirements
Pursue AABB (Cellular Therapy) If:
- Your program operates cellular therapy services as part of a broader blood banking and transfusion medicine program where AABB accreditation already covers your institutional operations
- Your cellular therapy program does not administer commercial CAR-T therapies and does not require Blue Distinction Center or Medicare CAR-T billing eligibility
- Your program has received AABB accreditation under prior standards and needs to transition to the 12th Edition (effective July 1, 2025)
Pursue Both If:
- Your institution operates both a FACT-required CAR-T or HCT program and a broader AABB-accredited blood banking or transfusion medicine program
- Your Compliance Crosswalk can be structured to address both FACT and AABB requirements simultaneously — IHS manages dual-standard programs
- State regulatory requirements specifically call for both standards (rare — verify state-specific requirements)
FACT 9th Edition vs. AABB 12th Edition: Key Standards Changes
FACT-JACIE 9th Edition (Effective February 2, 2026)
The 9th Edition represents the most significant structural overhaul of FACT-JACIE standards in recent years. Programs holding 8th Edition accreditation must update their Compliance Crosswalk, affected SOPs, and quality documentation before their next scheduled inspection.
- Consolidated Collection Standards. Peripheral blood stem cell collection, bone marrow collection, and tumor-infiltrating lymphocyte (TIL) collection — previously in separate standard sections — consolidated into a unified Collection section. Programs that collected under multiple separate SOP frameworks must integrate documentation.
- New REMS Standards. ASTCT 80/20 Task Force requirements for Risk Evaluation and Mitigation Strategies (REMS) programs are now formally incorporated into FACT. Programs must demonstrate REMS compliance within the Compliance Crosswalk.
- ISBT 128 Labeling for Further Manufacturing. Products intended for pharma manufacturing partners must use ISBT 128 labeling from collection. Programs that supply apheresis products to manufacturers must implement ISBT 128 for these products even if they were previously using institutional labeling systems.
AABB 12th Edition (Effective July 1, 2025)
The AABB 12th Edition Standards for Cellular Therapy Services updated ISBT 128 labeling requirements and operational mechanics for cellular therapy programs. Programs transitioning from 11th Edition must update documentation and processes for labeling conformity.
- 24-month inspection cycle maintained
- Emphasis on ISBT 128 labeling conformity — consistent with FACT 9th Edition's parallel ISBT 128 requirements
- Operational mechanics for cellular therapy product handling and storage
For programs managing both standards transitions simultaneously, the ISBT 128 labeling requirement is shared across both — implementing it once satisfies both FACT 9th Edition and AABB 12th Edition requirements. IHS structures dual-standard transition projects to leverage this overlap and reduce total documentation burden.
Frequently Asked Questions
Can AABB accreditation substitute for FACT accreditation in a CAR-T program?
No. Commercial CAR-T manufacturers reference FACT accreditation specifically in their authorized treatment center requirements. BCBS Blue Distinction Center for Transplants designation requires FACT accreditation including IEC Standards compliance. Medicare CAR-T coverage is tied to FACT-accredited programs. AABB accreditation is not a substitute for any of these requirements. Programs that hold only AABB accreditation are not authorized treatment centers for commercial CAR-T manufacturers and are excluded from BCBS reimbursement for CAR-T infusions.
How long does FACT accreditation take compared to AABB?
FACT accreditation requires 12 to 24 months of preparation for initial accreditation — driven primarily by the mandatory minimum volume requirements (allogeneic: minimum 10 new patients at the clinical site; autologous: minimum 5 patients; cord blood banks: minimum 500 units) and the Compliance Crosswalk development timeline. AABB accreditation preparation is typically shorter — the 24-month inspection cycle and less demanding Crosswalk equivalent reduces preparation time for programs with established cellular therapy infrastructure. Programs building new CAR-T programs from scratch should budget 18-24 months for FACT accreditation from engagement inception to accreditation award.
What is the FACT Compliance Crosswalk and does AABB require an equivalent?
The FACT Compliance Crosswalk is the central document that maps every FACT standard to the clinical program's internal policies, SOPs, and quality documents. FACT's Accreditation Coordinator reviews the Crosswalk off-site before scheduling an on-site inspection — a program with an incomplete or disorganized Crosswalk will not advance to inspection. The Crosswalk is IHS's first deliverable in every FACT engagement. AABB does not require an equivalent central Crosswalk document in the same format, though documentation of compliance with each standard section is still required for the AABB assessment.
Does IHS manage FACT and AABB accreditation simultaneously?
Yes. IHS structures dual-standard engagements to maximize documentation overlap between FACT and AABB requirements. The Quality Management Plan built for FACT accreditation addresses the QMS requirements in both standards. The ISBT 128 labeling implementation required by FACT 9th Edition also satisfies AABB 12th Edition labeling requirements. The primary additional work for AABB is the separate inspection cycle and the AABB-specific documentation format. IHS scopes dual-standard engagements with a single unified document library and two separate compliance maps.
What happens if a FACT-accredited program also needs to comply with FDA GMP requirements?
Programs involved in investigational cellular therapy trials or commercial manufacturing activities may need to comply with FDA GMP (Good Manufacturing Practice) requirements under 21 CFR Parts 210/211 or 21 CFR Part 1271, in addition to FACT accreditation standards. FACT accreditation and FDA GMP compliance are parallel frameworks — FACT addresses clinical program quality; FDA GMP addresses manufacturing quality. IHS advises on the interaction between FACT accreditation, AABB accreditation, and FDA regulatory requirements for programs operating in both clinical and manufacturing contexts.
Not Sure Whether Your Program Needs FACT, AABB, or Both?
IHS provides cellular therapy accreditation strategy consultations — helping program directors determine the right accreditation pathway, scope, and timeline based on their specific CAR-T or HCT program objectives, payer requirements, and manufacturer relationships.